Long COVID is defined as symptoms persisting after 4 weeks or 3 months, depending on the definition chosen (see Definition).[2]World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. October 2021 [internet publication].
https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
The majority of people will recover from coronavirus disease 2019 (COVID-19) within the first 12 weeks. After 12 weeks, patients may still recover but persistent illness becomes more likely or patients may improve but at a slower rate.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[78]Greenhalgh T, Sivan M, Delaney B, et al. Long covid-an update for primary care. BMJ. 2022 Sep 22;378:e072117.
https://www.doi.org/10.1136/bmj-2022-072117
http://www.ncbi.nlm.nih.gov/pubmed/36137612?tool=bestpractice.com
It is a heterogeneous condition that encompasses a wide spectrum of new or persistent symptoms following acute COVID-19 and includes individuals who were mildly ill and did not require care during the acute period of infection as well as those recovering from critical illness.[79]O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023 Jan;55:101762.
https://www.doi.org/10.1016/j.eclinm.2022.101762
http://www.ncbi.nlm.nih.gov/pubmed/36474804?tool=bestpractice.com
Use a holistic, person-centred approach that includes a comprehensive clinical history and appropriate examination.
Long COVID is a diagnosis of exclusion.[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
The primary goal of initial evaluation should be to focus on ruling out contributory factors that may be leading to ongoing symptoms (e.g., cardiac, pulmonary, and rheumatological processes).[2]World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. October 2021 [internet publication].
https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
Individuals with long COVID should also be screened for other post-viral conditions including myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia syndrome.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
Refer the patient to a specialist when the diagnosis is uncertain, there is concern for underlying organ-specific dysfunction (e.g., cardiac or pulmonary), or when symptoms are progressing or severe.[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
History
Ask if the patient has ever had confirmed or suspected COVID-19. A positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral test is not necessary to establish a diagnosis of long COVID. A long COVID diagnosis can be made on the basis of a previous patient-reported or clinical diagnosis of COVID-19.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[39]Herman E, Shih E, Cheng A. Long COVID: rapid evidence review. Am Fam Physician. 2022 Nov;106(5):523-32.
http://www.ncbi.nlm.nih.gov/pubmed/36379497?tool=bestpractice.com
Take a directed history aimed at the chief complaint for any patient presenting with concern for long COVID.
Ask about the frequency and severity of the symptoms (so that management of the most frequent and severe can be prioritised) and whether anything triggers, alleviates, or aggravates the symptoms.[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
Ask how symptoms, such as fatigue, affect the patient’s normal day-to-day functioning and impact on work or school.[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[82]Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43.
http://www.ncbi.nlm.nih.gov/pubmed/34346558?tool=bestpractice.com
Ask about the course and severity of the patient’s acute COVID-19 episode (if known).[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
Enquire about the patient’s activity level since COVID-19 and any new diagnoses or complications acquired since the episode.[83]Maley JH, Alba GA, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jan;14(1):77-95.
https://www.doi.org/10.1002/pmrj.12744
http://www.ncbi.nlm.nih.gov/pubmed/34902224?tool=bestpractice.com
Where possible, perform a comprehensive review of systems, bearing in mind the diverse nature of persistent symptoms associated with long COVID.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
However, due to time or resource constraints it may be necessary to prioritise which symptoms to focus on. Recognise that the symptoms of long COVID can have a major impact on the patient’s day-to-day life, ability to function, and sense of wellbeing. Ask the patient which symptoms are most troubling and use this to direct the further assessments, if needed. Consider using symptom questionnaires together with clinical assessment to identify the presence of symptoms and for changes over time.[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
A selection of recommended standardised measures and scales related to specific clinical symptoms are listed below (this is not an exhaustive list).[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[84]Munblit D, Nicholson T, Akrami A, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022 Jul;10(7):715-24.
https://www.doi.org/10.1016/S2213-2600(22)00169-2
http://www.ncbi.nlm.nih.gov/pubmed/35714658?tool=bestpractice.com
[85]Mikkelsen ME, Still M, Anderson BJ, et al. Society of Critical Care Medicine's international consensus conference on prediction and identification of long-term impairments after critical illness. Crit Care Med. 2020 Nov;48(11):1670-9.
http://www.ncbi.nlm.nih.gov/pubmed/32947467?tool=bestpractice.com
Respiratory function
Modified Medical Research Council Dyspnoea Scale
Opens in new window
Borg Dyspnea Scale
Multidimensional Dyspnea Profile[83]Maley JH, Alba GA, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jan;14(1):77-95.
https://www.doi.org/10.1002/pmrj.12744
http://www.ncbi.nlm.nih.gov/pubmed/34902224?tool=bestpractice.com
Fatigue
Post-exertional symptoms
Cardiovascular symptoms
Cognitive function
Mental health
Nervous system symptoms
Pain
Brief Pain Inventory
Visual Analogue Scale
Work/occupation
Recovery
Multiple domains
The presentation of long COVID is varied, with over 200 symptoms having been linked to the condition.[13]Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 Aug;38:101019.
https://www.doi.org/10.1016/j.eclinm.2021.101019
http://www.ncbi.nlm.nih.gov/pubmed/34308300?tool=bestpractice.com
Symptoms may fluctuate, persist, relapse, and remit over time.[3]World Health Organization. Clinical management of COVID-19: living guideline. August 2023 [internet publication].
https://app.magicapp.org/#/guideline/j1WBYn
Prevalence rates of long COVID symptoms have been limited by methodological issues, including lack of control groups, unknown prevalence of pre-COVID symptoms, inconsistent assessments, and heterogeneity of populations being studied. Despite these limitations, the most common symptoms of long COVID are generally reported to include:
Fatigue/weakness (31% to 58%)[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[8]Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023 Jun 13;329(22):1934-46.
https://www.doi.org/10.1001/jama.2023.8823
http://www.ncbi.nlm.nih.gov/pubmed/37278994?tool=bestpractice.com
[18]Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022 Aug 6;400(10350):452-61.
https://www.doi.org/10.1016/S0140-6736(22)01214-4
http://www.ncbi.nlm.nih.gov/pubmed/35934007?tool=bestpractice.com
[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[79]O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023 Jan;55:101762.
https://www.doi.org/10.1016/j.eclinm.2022.101762
http://www.ncbi.nlm.nih.gov/pubmed/36474804?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
[86]Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.
https://www.doi.org/10.1136/bmjgh-2021-005427
http://www.ncbi.nlm.nih.gov/pubmed/34580069?tool=bestpractice.com
Cognitive impairment (brain fog) (12% to 35%)[8]Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023 Jun 13;329(22):1934-46.
https://www.doi.org/10.1001/jama.2023.8823
http://www.ncbi.nlm.nih.gov/pubmed/37278994?tool=bestpractice.com
[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
[86]Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.
https://www.doi.org/10.1136/bmjgh-2021-005427
http://www.ncbi.nlm.nih.gov/pubmed/34580069?tool=bestpractice.com
Impaired sleep (11% to 44%)[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[79]O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023 Jan;55:101762.
https://www.doi.org/10.1016/j.eclinm.2022.101762
http://www.ncbi.nlm.nih.gov/pubmed/36474804?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
Headache (up to 79%)[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
Dizziness (up to 48%)[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[8]Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023 Jun 13;329(22):1934-46.
https://www.doi.org/10.1001/jama.2023.8823
http://www.ncbi.nlm.nih.gov/pubmed/37278994?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
Dyspnoea (22% to 40%)[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[18]Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022 Aug 6;400(10350):452-61.
https://www.doi.org/10.1016/S0140-6736(22)01214-4
http://www.ncbi.nlm.nih.gov/pubmed/35934007?tool=bestpractice.com
[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[79]O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023 Jan;55:101762.
https://www.doi.org/10.1016/j.eclinm.2022.101762
http://www.ncbi.nlm.nih.gov/pubmed/36474804?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
[86]Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.
https://www.doi.org/10.1136/bmjgh-2021-005427
http://www.ncbi.nlm.nih.gov/pubmed/34580069?tool=bestpractice.com
Loss of concentration (60%)[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
Cough (7% to 29%)[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
Anosmia/dysgeusia (10% to 46%)[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[18]Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022 Aug 6;400(10350):452-61.
https://www.doi.org/10.1016/S0140-6736(22)01214-4
http://www.ncbi.nlm.nih.gov/pubmed/35934007?tool=bestpractice.com
[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
Pain (including arthralgias and myalgias) (9% to 19%)[18]Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022 Aug 6;400(10350):452-61.
https://www.doi.org/10.1016/S0140-6736(22)01214-4
http://www.ncbi.nlm.nih.gov/pubmed/35934007?tool=bestpractice.com
[79]O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023 Jan;55:101762.
https://www.doi.org/10.1016/j.eclinm.2022.101762
http://www.ncbi.nlm.nih.gov/pubmed/36474804?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
Chest pain (6% to 17%)[18]Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022 Aug 6;400(10350):452-61.
https://www.doi.org/10.1016/S0140-6736(22)01214-4
http://www.ncbi.nlm.nih.gov/pubmed/35934007?tool=bestpractice.com
[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
Post-exertional malaise[8]Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023 Jun 13;329(22):1934-46.
https://www.doi.org/10.1001/jama.2023.8823
http://www.ncbi.nlm.nih.gov/pubmed/37278994?tool=bestpractice.com
[86]Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.
https://www.doi.org/10.1136/bmjgh-2021-005427
http://www.ncbi.nlm.nih.gov/pubmed/34580069?tool=bestpractice.com
Anxiety/depression[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
Other common symptoms include:
Palpitations[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
Thirst/dry mouth
Loss of sexual drive or capacity
Numbness/tingling
Hair loss
Abnormal movements
Gastrointestinal symptoms[8]Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023 Jun 13;329(22):1934-46.
https://www.doi.org/10.1001/jama.2023.8823
http://www.ncbi.nlm.nih.gov/pubmed/37278994?tool=bestpractice.com
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
The following symptoms and signs are less commonly reported in children and younger people:[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
Dyspnoea
Persistent cough
Pain on breathing
Palpitations
Heart rate variations
Chest pain.
Ask the patient about comorbidities and review any drugs that the patient is taking as these may be contributing to ongoing symptoms.[82]Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43.
http://www.ncbi.nlm.nih.gov/pubmed/34346558?tool=bestpractice.com
[Figure caption and citation for the preceding image starts]: Co-occurrence network of symptom clusters 6-12 months after acute infection. Outer circles represent individual symptoms. Circle area represents proportion of patients with that symptom. These are linked to inner circles, which represent symptom clusters. Width of link lines again represents proportion of patients with that symptom. Circle area for clusters represents proportion of patients with at least one symptom from that cluster. Central links between symptom clusters represent co-occurrence of symptom clusters. Link width represents degree of co-occurrence. Based on data from 11,536 participants. Only symptoms not present before acute SARS-CoV-2 infection were consideredBMJ 2022 Oct 13:379:e071050; used with permission [Citation ends].
Risk factors
Risk factors for long COVID include having a more severe acute COVID-19 illness (including being hospitalised), partial vaccination or absence of vaccination against COVID-19, and female sex. Other risk factors include age older than 40 years, body mass index >30 kg/m², being a current smoker, and presence of comorbidities.[10]Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022 Oct 25;328(16):1604-15.
https://www.doi.org/10.1001/jama.2022.18931
http://www.ncbi.nlm.nih.gov/pubmed/36215063?tool=bestpractice.com
[33]Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-8.
https://www.doi.org/10.15585/mmwr.mm6930e1
http://www.ncbi.nlm.nih.gov/pubmed/32730238?tool=bestpractice.com
[34]Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021 Sep;114(9):428-42.
https://www.doi.org/10.1177/01410768211032850
http://www.ncbi.nlm.nih.gov/pubmed/34265229?tool=bestpractice.com
[35]Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022 Jan;22(1):43-55.
https://www.doi.org/10.1016/S1473-3099(21)00460-6
http://www.ncbi.nlm.nih.gov/pubmed/34480857?tool=bestpractice.com
[36]Crook H, Raza S, Nowell J, et al. Long covid-mechanisms, risk factors, and management. BMJ. 2021 Jul 26;374:n1648.
http://www.ncbi.nlm.nih.gov/pubmed/34312178?tool=bestpractice.com
[37]Kamal M, Abo Omirah M, Hussein A, et al. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021 Mar;75(3):e13746.
http://www.ncbi.nlm.nih.gov/pubmed/32991035?tool=bestpractice.com
[38]Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.
https://www.doi.org/10.7326/M21-4905
http://www.ncbi.nlm.nih.gov/pubmed/35605238?tool=bestpractice.com
[39]Herman E, Shih E, Cheng A. Long COVID: rapid evidence review. Am Fam Physician. 2022 Nov;106(5):523-32.
http://www.ncbi.nlm.nih.gov/pubmed/36379497?tool=bestpractice.com
[40]Azzolini E, Levi R, Sarti R, et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022 Aug 16;328(7):676-8.
https://www.doi.org/10.1001/jama.2022.11691
http://www.ncbi.nlm.nih.gov/pubmed/35796131?tool=bestpractice.com
[41]Wang S, Quan L, Chavarro JE, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. JAMA Psychiatry. 2022 Nov 1;79(11):1081-91.
https://www.doi.org/10.1001/jamapsychiatry.2022.2640
http://www.ncbi.nlm.nih.gov/pubmed/36069885?tool=bestpractice.com
[42]Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023 Jun 1;183(6):566-80.
https://www.doi.org/10.1001/jamainternmed.2023.0750
http://www.ncbi.nlm.nih.gov/pubmed/36951832?tool=bestpractice.com
[43]Maglietta G, Diodati F, Puntoni M, et al. Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J Clin Med. 2022 Mar 11;11(6):1541.
https://www.doi.org/10.3390/jcm11061541
http://www.ncbi.nlm.nih.gov/pubmed/35329867?tool=bestpractice.com
[44]Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684-9.
https://www.doi.org/10.1016/S1473-3099(23)00684-9
http://www.ncbi.nlm.nih.gov/pubmed/38104583?tool=bestpractice.com
Physical examination
Ideally, perform comprehensive cardiopulmonary, neurological, and rheumatological examinations. Further direct the physical examinations depending on the presenting symptoms.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
See Assessment of dyspnea, Assessment of fatigue, Assessment of dizziness, Assessment of chronic cough, Assessment of chest pain.
Obtain vital signs, including heart rate, blood pressure, respiratory rate, pulse oximetry, and body temperature.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
[83]Maley JH, Alba GA, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jan;14(1):77-95.
https://www.doi.org/10.1002/pmrj.12744
http://www.ncbi.nlm.nih.gov/pubmed/34902224?tool=bestpractice.com
For patients presenting with activity intolerance, fatigue, cognitive impairment, generalised malaise, dyspnoea, dizziness, and/or palpitations, obtain a 10-minute orthostatic stand test with measurement of heart rate and blood pressure at 5 minutes after laying supine and 1, 2, 5, and 10 minutes after standing.[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
[87]Blitshteyn S, Whiteson JH, Abramoff B, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Oct;14(10):1270-91.
http://www.ncbi.nlm.nih.gov/pubmed/36169154?tool=bestpractice.com
This will help to differentiate cardiovascular symptoms from autonomic dysfunction.[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
A sustained drop in blood pressure of ≥20/10 mmHg within 3 minutes of standing or on a tilt table test indicates orthostatic hypotension. A sustained heart rate increase ≥30 beats per minute within 10 minutes for adults (≥40 beats per minute for adolescents aged 12-19 years) of standing or on a tilt table test is an indicator (amongst other criteria) for postural orthostatic tachycardia syndrome.[87]Blitshteyn S, Whiteson JH, Abramoff B, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Oct;14(10):1270-91.
http://www.ncbi.nlm.nih.gov/pubmed/36169154?tool=bestpractice.com
Obtain standardised measures of endurance and activity performance at the initial examination.[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
For individuals with generalised malaise, fatigue, dyspnoea, or exertional intolerance, use a test such as a 6-minute walk test with assessment of ambulatory oxygenation, 30-second (or 1-minute) sit-to-stand test, a 2‐minute step (seated or standing), or a 10-metre walk test.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[82]Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43.
http://www.ncbi.nlm.nih.gov/pubmed/34346558?tool=bestpractice.com
Consider the degree of post-exertional malaise prior to any testing of endurance and activity performance. Use caution as the patient may not have the stamina or capability to perform these physical tests and such tests may worsen the patient’s symptoms of fatigue or malaise in the following days.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
Additional planning and modifications of the tests may be required in patients with post-exertional malaise.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
Repeat the measures at follow-up to compare with previous results and guide intervention.[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
Bear in mind that a combination of factors, such as fatigue and dyspnoea, may contribute to a patient’s limited activity level.
Initial investigations
Long COVID is primarily a clinical diagnosis. Investigations should be directed at ruling out other, directly treatable conditions.[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
Tests should be selective and tailored to the patient’s symptoms.[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[78]Greenhalgh T, Sivan M, Delaney B, et al. Long covid-an update for primary care. BMJ. 2022 Sep 22;378:e072117.
https://www.doi.org/10.1136/bmj-2022-072117
http://www.ncbi.nlm.nih.gov/pubmed/36137612?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
There is no direct testing for long COVID and no definitive test to rule in or rule out the condition.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
Laboratory tests and imaging are typically normal. Normal objective test results or findings should not be used to dismiss the presence or severity of a patient’s symptoms or as the only measure of their overall wellbeing.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
For all patients with suspected long COVID, obtain a basic laboratory panel including:[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[39]Herman E, Shih E, Cheng A. Long COVID: rapid evidence review. Am Fam Physician. 2022 Nov;106(5):523-32.
http://www.ncbi.nlm.nih.gov/pubmed/36379497?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
[82]Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43.
http://www.ncbi.nlm.nih.gov/pubmed/34346558?tool=bestpractice.com
[88]US Department of Veterans Affairs. Whole health system approach to long COVID. August 2022 [internet publication].
https://www.publichealth.va.gov/n-coronavirus/docs/Whole-Health-System-Approach-to-Long-COVID_080122_FINAL.pdf
Full blood count
Comprehensive metabolic panel
Creatine kinase
C-reactive protein
Erythrocyte sedimentation rate
Ferritin
Thyroid stimulating hormone and free T4
Vitamin D and B12.
A positive SARS-CoV-2 viral test is not necessary to establish a diagnosis of long COVID. A long COVID diagnosis can be made on the basis of a previous patient-reported or clinical diagnosis of COVID-19.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[39]Herman E, Shih E, Cheng A. Long COVID: rapid evidence review. Am Fam Physician. 2022 Nov;106(5):523-32.
http://www.ncbi.nlm.nih.gov/pubmed/36379497?tool=bestpractice.com
Other investigations
Subsequent testing is based on presenting symptoms and degree of clinical suspicion. Generally, additional testing is not needed unless there is a specific condition that there is concern for. Risks of excess testing include increased risk of incidental findings, anxiety, radiation exposure, cost, time, and energy.[4]Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
[39]Herman E, Shih E, Cheng A. Long COVID: rapid evidence review. Am Fam Physician. 2022 Nov;106(5):523-32.
http://www.ncbi.nlm.nih.gov/pubmed/36379497?tool=bestpractice.com
[82]Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43.
http://www.ncbi.nlm.nih.gov/pubmed/34346558?tool=bestpractice.com
For persistent dyspnoea, obtain pulmonary function testing and consider (in addition to the initial investigations):[1]National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].
https://www.nice.org.uk/guidance/ng188
[78]Greenhalgh T, Sivan M, Delaney B, et al. Long covid-an update for primary care. BMJ. 2022 Sep 22;378:e072117.
https://www.doi.org/10.1136/bmj-2022-072117
http://www.ncbi.nlm.nih.gov/pubmed/36137612?tool=bestpractice.com
[80]Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.
https://www.doi.org/10.1016/j.cmi.2022.02.018
http://www.ncbi.nlm.nih.gov/pubmed/35182760?tool=bestpractice.com
[83]Maley JH, Alba GA, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jan;14(1):77-95.
https://www.doi.org/10.1002/pmrj.12744
http://www.ncbi.nlm.nih.gov/pubmed/34902224?tool=bestpractice.com
[88]US Department of Veterans Affairs. Whole health system approach to long COVID. August 2022 [internet publication].
https://www.publichealth.va.gov/n-coronavirus/docs/Whole-Health-System-Approach-to-Long-COVID_080122_FINAL.pdf
B-type natriuretic peptide
D-dimer
Chest radiography
Chest computed tomography (CT)
Transthoracic echocardiogram.
In a group of hospitalised patients evaluated by chest CT, 55.7% had residual abnormalities on chest CT at 3 months.[89]So M, Kabata H, Fukunaga K, et al. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021 Mar 22;21(1):97.
https://www.doi.org/10.1186/s12890-021-01463-0
http://www.ncbi.nlm.nih.gov/pubmed/33752639?tool=bestpractice.com
After 1 year, 32.6% of hospitalised patients still had residual CT abnormalities (primarily fibrotic changes). Abnormalities were more frequent in patients who had severe/critical disease compared with mild/moderate disease.[90]Watanabe A, So M, Iwagami M, et al. One-year follow-up CT findings in COVID-19 patients: a systematic review and meta-analysis. Respirology. 2022 Aug;27(8):605-16.
https://www.doi.org/10.1111/resp.14311
http://www.ncbi.nlm.nih.gov/pubmed/35694728?tool=bestpractice.com
However, the prevalence of lung sequelae at 1 year is highly heterogeneous among studies.[91]Bocchino M, Rea G, Capitelli L, et al. Chest CT lung abnormalities 1 year after COVID-19: a systematic review and meta-analysis. Radiology. 2023 Jul;308(1):e230535.
https://www.doi.org/10.1148/radiol.230535
http://www.ncbi.nlm.nih.gov/pubmed/37404150?tool=bestpractice.com
For persistent cardiac symptoms, consider (in addition to the initial investigations):[81]Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78.
http://www.ncbi.nlm.nih.gov/pubmed/35657351?tool=bestpractice.com
B-type natriuretic peptide
D-dimer, troponin
Chest x-ray
Electrocardiogram
Transthoracic echocardiogram
Exercise stress test
Cardiopulmonary exercise test
Ambulatory heart rate monitoring
Cardiac magnetic resonance imaging (MRI).
For persistent symptoms of autonomic dysfunction, consider (in addition to the initial investigations):[87]Blitshteyn S, Whiteson JH, Abramoff B, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Oct;14(10):1270-91.
http://www.ncbi.nlm.nih.gov/pubmed/36169154?tool=bestpractice.com
Morning cortisol
Anti-nuclear antibodies
D-dimer (if concern for pulmonary embolism)
Autonomic reflex testing
Tilt-table testing
Electrocardiogram
Ambulatory heart rate monitoring
Transthoracic echocardiogram.
For persistent cognitive issues, consider (in addition to the initial investigations):[92]Fine JS, Ambrose AF, Didehbani N, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jan;14(1):96-111.
https://www.doi.org/10.1002/pmrj.12745
http://www.ncbi.nlm.nih.gov/pubmed/34902226?tool=bestpractice.com
For rheumatological symptoms, consider (in addition to the initial investigations):[82]Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43.
http://www.ncbi.nlm.nih.gov/pubmed/34346558?tool=bestpractice.com
[93]Mueller MR, Ganesh R, Hurt RT, et al. Post-COVID conditions. Mayo Clin Proc. 2023 Jul;98(7):1071-8.
https://www.doi.org/10.1016/j.mayocp.2023.04.007
http://www.ncbi.nlm.nih.gov/pubmed/37419575?tool=bestpractice.com
Imaging of affected joints
Anti-nuclear antibody test
Rheumatoid factor
Anti-cyclic citrullinated peptide
Anti-cardiolipin antibody.
For persistent fatigue, consider (in addition to the initial investigations) an overnight sleep study (if suspecting sleep apnoea).[82]Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43.
http://www.ncbi.nlm.nih.gov/pubmed/34346558?tool=bestpractice.com